• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A functional quantitative receptor assay using flluoscein labeled hormones with a carbohydrate chain for the evaluation of the hormonal replacement therapy

Research Project

Project/Area Number 21590621
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Laboratory medicine
Research InstitutionHamamatsu University School of Medicine

Principal Investigator

ONO Takaaki (2010-2011)  浜松医科大学, がん教育研究センター, 特任助教 (40402276)

竹下 香 (新庄 香) (2009)  Hamamatsu University School of Medicine, 保健管理センター, 特任助教 (30397393)

Co-Investigator(Kenkyū-buntansha) TAKESHITA Akihiro  浜松医科大学, 医学部, 准教授 (00242769)
OHNISHI Kazunori  浜松医科大学, 医学部附属病院, 教授 (80252170)
小野 孝明  浜松医科大学, がん教育研究センター, 特任助教 (40402276)
Project Period (FY) 2009 – 2011
Project Status Completed (Fiscal Year 2011)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Keywordsホルモン / TSH / ビオチン化 / フローサイトメトリー / 糖鎖 / 受容体
Research Abstract

We have studied a non-isotopic ligand binding assay with the flow cytometry using biotinylated cytokines and fluorescent dye labeled streptavidin. Also, we have enabled to analyze a very small amount of receptors quantitatively according to the cell surface antigen by multicolor flow cytometry even in the heterogeneous cell population. In this study, we examined the possibility of applying the non-isotopic ligand binding assay with the flow cytometry into the hormone receptor assay. We examined the possibility of analysis of the thyrotropin(TSH) receptor expression by using recombinant human TSH(rhTSH) and FRTL-5 cell line which expresses TSH receptors. We biotinylated the rhTSH according to the previous studies in cytokines. D value, which is one of the components of Kormogonov-Smirnov statistics in flow cytometry, is useful for quantitative analysis of hormone receptor. If the assay system has enough sensitivity and specificity, D value is significantly high(p<0. 01). In clinical usage including the analyses using human serum, maximum D value should be needed more than 0. 50. We improved the efficacy of biotinylation to rhTSH and incubation methods. In this study, we tried to label the fluorescent dye to the rhTSH directly. Maximum D value improved to 0. 12, which meant specific binding. However, it should be considered about the more effective intensification of biotinylation or fluorescent labeling of the rhTSH.

Report

(4 results)
  • 2011 Annual Research Report   Final Research Report ( PDF )
  • 2010 Annual Research Report
  • 2009 Annual Research Report
  • Research Products

    (54 results)

All 2012 2011 2010 2009

All Journal Article (28 results) (of which Peer Reviewed: 28 results) Presentation (20 results) Book (6 results)

  • [Journal Article] Long-term outcome of imatinib therapy, with assessment of its dosage and blood levels, for chronic myelogenous leukemia2012

    • Author(s)
      Ohnishi K., et al
    • Journal Title

      Cancer Science

      Volume: (in press)

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Long-term outcome of imatinib therapy, with assessment of its dosage and blood levels, for chronic myelogenous leukemia2012

    • Author(s)
      Ohnishi K, et al
    • Journal Title

      Cancer Science

      Volume: (In press) Issue: 6 Pages: 1071-1078

    • DOI

      10.1111/j.1349-7006.2012.02253.x

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome positive leukemia by use of the PCR-Invader assay2011

    • Author(s)
      Ono T, et al
    • Journal Title

      Leukemia Research

      Volume: 35(5) Pages: 598-603

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia : 10-year results of the Japan Adult Leukemia Study Group APL97 study2011

    • Author(s)
      Ono T, Takeshita A, et al
    • Journal Title

      Haematologica

      Volume: 96(1) Pages: 174-176

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Transcriptional repression of Cdc25B by IER5 inhibits the proliferation of leukemic progenitor cells through NF-YB and p300 in acute myeloid leukemia2011

    • Author(s)
      Nakamura S, Ohnishi K., et al
    • Journal Title

      PLoS One

      Volume: 6(11)

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells2011

    • Author(s)
      Nakamura S, Ohnishi K., et al
    • Journal Title

      Carcinogenesis

      Volume: 32(12) Pages: 1758-72

    • Related Report
      2011 Annual Research Report 2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia(AML): Japan Adult Leukemia Study Group(JALSG)-AML206 study2011

    • Author(s)
      Usui N, Ohnishi K., et al
    • Journal Title

      Cancer Science

      Volume: 102(7) Pages: 1358-65

    • NAID

      10029295449

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes2011

    • Author(s)
      Uchida T, Ohnishi K., et al
    • Journal Title

      Cancer Science

      Volume: 102(9) Pages: 1680-6

    • NAID

      10030243114

    • Related Report
      2011 Annual Research Report 2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia2011

    • Author(s)
      Nakamura S, Ohnishi K., et al
    • Journal Title

      Molecular Carcinogenesis

      Volume: (in press)

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Nilotinib as frontline therapy for patients with newly diagnosed Ph+chronic myeloid leukemia in chronic phase : results from the Japanese subgroup of ENESTnd2011

    • Author(s)
      Nakamae H, Ohnishi K., et al
    • Journal Title

      International journal of hematology

      Volume: 93(5) Pages: 624-632

    • NAID

      10029535125

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Transcriptional repression of Cdc25B by IER5 inhibits the proliferation of leukemic progenitor cells through NF-YB and p300 in acute myeloid leukemia2011

    • Author(s)
      Nakamura S, Ohnishi K, et al
    • Journal Title

      PLoS One

      Volume: 6(11) Issue: 11 Pages: e28011-e28011

    • DOI

      10.1371/journal.pone.0028011

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia (AML) : Japan Adult Leukemia study Group (JALSG)-AML206 study2011

    • Author(s)
      Usui N, Ohnishi K, et al
    • Journal Title

      Cancer Science

      Volume: 102(7) Issue: 7 Pages: 1358-65

    • DOI

      10.1111/j.1349-7006.2011.01957.x

    • NAID

      10029295449

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] JmjC-domain containing histone demethylase 1B-mediated P15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia2011

    • Author(s)
      Nakamura S, Ohnishi K, et al
    • Journal Title

      Molecular Carcinogenesis

      Volume: (In press) Issue: 1 Pages: 57-69

    • DOI

      10.1002/mc.20878

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase : results from the Japanese subgroup of ENESTnd2011

    • Author(s)
      Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, Nagai T, Ohnishi K, Maeda Y, Matsuda A, Amagasaki T, Yanada M
    • Journal Title

      International Journal of Hematology

      Volume: 93 Issue: 5 Pages: 624-632

    • DOI

      10.1007/s12185-011-0841-8

    • NAID

      10029535125

    • Related Report
      2011 Annual Research Report
    • Peer Reviewed
  • [Journal Article] BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.2011

    • Author(s)
      Ono T, et al
    • Journal Title

      Leukemia Research

      Volume: (in press)

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia : 10-year results of the Japan Adult Leukemia Study Group APL97 study.2011

    • Author(s)
      Ono T, Takeshita A, et al
    • Journal Title

      Haematologica

      Volume: 96(1) Pages: 174-176

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia2010

    • Author(s)
      Nakamura S, Ono T, et al
    • Journal Title

      Carcinogenesis

      Volume: 31(11) Pages: 2012-2021

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation2010

    • Author(s)
      Takemura T, Ono T, et al
    • Journal Title

      The Journal of Biological Chemistry

      Volume: 285(9) Pages: 6585-6594

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity2010

    • Author(s)
      Nakamura S, Ono T, et al
    • Journal Title

      Investigational New Drugs

      Volume: 28(4) Pages: 381-391

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia.2010

    • Author(s)
      Nakamura S, Ono T, et al
    • Journal Title

      Carcinogenesis

      Volume: 31(11) Pages: 2012-2021

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.2010

    • Author(s)
      Takemura T, Oho T, et al
    • Journal Title

      The Journal of Biological Chemistry

      Volume: 285(9) Pages: 6585-6594

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity.2010

    • Author(s)
      Nakamura S, Ono T, et al
    • Journal Title

      Investigational New Drugs

      Volume: 28(4) Pages: 381-391

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] CMC-544(inotuzumab ozogamicin) shows less effect on multidrug resistant cells : analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma2009

    • Author(s)
      Takeshita A, Ono T, et al
    • Journal Title

      Br J Haematol

      Volume: 136 Pages: 34-43

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] CMC-544(inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells2009

    • Author(s)
      Takeshita A, Ono T, et al
    • Journal Title

      Leukemia

      Volume: 23 Pages: 1329-1336

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study2009

    • Author(s)
      Kobayashi Y, Takeshita A, et al
    • Journal Title

      Int J Hematol

      Volume: 89 Pages: 460-469

    • NAID

      10025161243

    • Related Report
      2011 Final Research Report
    • Peer Reviewed
  • [Journal Article] CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells : analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymnhoma2009

    • Author(s)
      Takeshita A, et al.
    • Journal Title

      Br J Haematol 146

      Pages: 34-43

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells2009

    • Author(s)
      Takeshita A, et al.
    • Journal Title

      Leukemia 23

      Pages: 1329-1336

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia : final results of Japanese multicenter cooperative study2009

    • Author(s)
      Kobayashi Y, et al.
    • Journal Title

      Int J Hematol 89

      Pages: 460-469

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Presentation] Clinical features and prognostic impact of CD56 expression in acute promyelocytic leukemia : Long term follow up data from the Japan Adult Leukemia Study Group(JALSG) APL972011

    • Author(s)
      Ono T, Takeshita A, et al
    • Organizer
      53nd ASH Annual Meeting and Exposition
    • Place of Presentation
      San Diego Convention Center, San Diego, U. S. A
    • Year and Date
      2011-12-12
    • Related Report
      2011 Final Research Report
  • [Presentation] Clinical features and prognostic impact of CD56 expression in acute promyelocytic leukemia : Long term follow up data from the Japan Adult Leukemia Study Group (JALSG) APL972011

    • Author(s)
      Ono T, Takeshita A, et al
    • Organizer
      American Society of Hematology (ASH) Annual Meeting and Exposition (53nd)
    • Place of Presentation
      San Diego, CA, San Diego Convention Center
    • Year and Date
      2011-12-12
    • Related Report
      2011 Annual Research Report
  • [Presentation] Clinical impact of CD56 expression in APL ; Results from the Japan Adult Leukemia Study Group APL972011

    • Author(s)
      Ono T, Takeshita A, et al
    • Organizer
      73^<rd> Annual Meeting of the Japanese Society of Hematology
    • Place of Presentation
      Nagoya, Japan
    • Year and Date
      2011-10-14
    • Related Report
      2011 Final Research Report
  • [Presentation] Clinical impact of CD56 expression in APL ; Results from the Japan Adult Leukemia Study Group APL972011

    • Author(s)
      小野孝明、竹下明裕
    • Organizer
      日本血液学会総会
    • Place of Presentation
      名古屋国際会議場
    • Year and Date
      2011-10-14
    • Related Report
      2011 Annual Research Report
  • [Presentation] Clinical features and outcomes in elderly patients with acute promyelocytic leukemia-the Japan Adult Leukemia Study Group APL97 study-2010

    • Author(s)
      Ono T, Takeshita A, et al
    • Organizer
      52nd ASH Annual Meeting and Exposition
    • Place of Presentation
      Orange County Convention Center, Orlando, USA
    • Year and Date
      2010-12-04
    • Related Report
      2011 Final Research Report
  • [Presentation] Clinical features and outcomes in elderly patients with acute promyelocytic leukemia -the Japan Adult Leukemia Study Group APL97 study-2010

    • Author(s)
      Ono T, Takeshita A, et al
    • Organizer
      American Society of Hematology (ASH) Annual Meeting and Exposition (52nd)
    • Place of Presentation
      Orlando, Florida, Orange County Convention Center
    • Year and Date
      2010-12-04
    • Related Report
      2010 Annual Research Report
  • [Presentation] The analysis of BCR-ABL1 mutations in imatinib-resistant Philadelphia Chromosome-positive leukemia2010

    • Author(s)
      Ono T, Ohnishi K, et al
    • Organizer
      72^<nd> Annual Meeting of the Japanese Society of Hematology
    • Place of Presentation
      Yokohama, Japan
    • Year and Date
      2010-09-26
    • Related Report
      2011 Final Research Report
  • [Presentation] The analysis of BCR-ABL1 mutations in imatinib-resistant Philadelphia Chromosome-positive leukemia2010

    • Author(s)
      小野孝明
    • Organizer
      第72回 日本血液学会学術集会 総会
    • Place of Presentation
      パシフィコ横浜(神奈川)
    • Year and Date
      2010-09-26
    • Related Report
      2010 Annual Research Report
  • [Presentation] Impact of additional chromosomal abnormalities(ACAs) in patients of acute promyelocytic leukemia 10 years follow up results of the Japan Adult Leukemia Study Group APL97 study2010

    • Author(s)
      Ono T, Takeshita A, et al
    • Organizer
      15^<th> Congress of the European Hematology Association
    • Place of Presentation
      Fira Barcelona Gran Via Conference Center, Barcelona, Spain
    • Year and Date
      2010-06-12
    • Related Report
      2011 Final Research Report
  • [Presentation] Impact of additional chromosomal abnormalities (ACAs) in patients of acute promyelocytic leukemia 10 years follow up results of the Japan Adult Leukemia Study Group APL97 study2010

    • Author(s)
      Ono T, Takeshita A, et al
    • Organizer
      15^<th> Congress of the European Hematology Association
    • Place of Presentation
      Barcelona, Spain, Fira Barcelona Gran Via Conference Center
    • Year and Date
      2010-06-12
    • Related Report
      2010 Annual Research Report
  • [Presentation] BCR-ABL1 mutations in Japanese patients with Ph-positive leukemia resistant to imatinib2010

    • Author(s)
      Ono T, Ohnishi K, et al
    • Organizer
      8^<th> Annual Meeting of Japanese Society of Medical Oncology
    • Place of Presentation
      Tokyo Japan
    • Year and Date
      2010-03-20
    • Related Report
      2011 Final Research Report
  • [Presentation] 日本のイマチニブ耐性Philadelphia染色体陽性白血病患者におけるBCR-ABL1点突然変異解析2010

    • Author(s)
      小野孝明
    • Organizer
      第8回日本臨床腫瘍学会学術集会 総会
    • Place of Presentation
      東京ビッグサイト(東京)
    • Year and Date
      2010-03-20
    • Related Report
      2010 Annual Research Report
  • [Presentation] Downregulation of THAP11 by Bcr-Abl Promotes c-Myc-Mediated CML Cell Proliferation2009

    • Author(s)
      Yokota D, Ono T, Ohnishi K et al
    • Organizer
      51st ASH Annual Meeting and Exposition
    • Place of Presentation
      New Orleans, U. S. A
    • Year and Date
      2009-12-07
    • Related Report
      2011 Final Research Report
  • [Presentation] Downregulation of THAP11 by Bcr-Abl Promotes c-Myc-Mediated CML Cell Proliferation2009

    • Author(s)
      Daisuke Yokota, et al.
    • Organizer
      51st ASH Annual Meeting and Exposition
    • Place of Presentation
      New Orleans, USA
    • Year and Date
      2009-12-07
    • Related Report
      2009 Annual Research Report
  • [Presentation] Depletion of PHLPP1 and 2 by Bcr-Abl Promotes CML Cell Proliferation through the Continuous Phosphorylation of Akt2009

    • Author(s)
      Hirano I, Ono T, Ohnishi K et al
    • Organizer
      51st ASH Annual Meeting and Exposition
    • Place of Presentation
      New Orleans, U. S. A
    • Year and Date
      2009-12-06
    • Related Report
      2011 Final Research Report
  • [Presentation] Depletion of PHLPP1 and 2 by Bcr-Abl Promotes CML Cell Proliferation through the Continuous Phosphorylation of Akt2009

    • Author(s)
      Isao Hirano, et al.
    • Organizer
      51st ASH Annual Meeting and Exposition
    • Place of Presentation
      New Orleans, USA
    • Year and Date
      2009-12-06
    • Related Report
      2009 Annual Research Report
  • [Presentation] Hematological malignancies : recent advances and future directions Treatment of CML in the era of molecular targeted therapy2009

    • Author(s)
      Ohnishi K, et al
    • Organizer
      68^<th> Annual Meeting of the Japanese Cancer Assosiation
    • Place of Presentation
      Yokohama, Japan
    • Year and Date
      2009-10-03
    • Related Report
      2011 Final Research Report 2009 Annual Research Report
  • [Presentation] Internalization may be important in the efficacy of CMC-544, a new calicheamicin-conjugated anti-CD22 antibody2009

    • Author(s)
      Takeshita A, et al
    • Organizer
      68^<th> Annual Meeting of the Japanese Cancer Assosiation
    • Place of Presentation
      Yokohama, Japan
    • Year and Date
      2009-10-02
    • Related Report
      2011 Final Research Report 2009 Annual Research Report
  • [Presentation] Depletion of PHLPP1, 2 by Bcr-Abl promotesCML cell proliferation through the continuousphosphorylation of Akt isoforms2009

    • Author(s)
      Nakamura S, Ohnishi K, et al
    • Organizer
      68^<th> Annual Meeting of the Japanese Cancer Assosiation
    • Place of Presentation
      Yokohama, Japan
    • Year and Date
      2009-10-02
    • Related Report
      2011 Final Research Report
  • [Presentation] Depletion of PHLPP1,2 by Bcr-Abl promotes CML cell proliferation through the continuous phosphorylation of Akt isoforms2009

    • Author(s)
      Nakamura S, et al.
    • Organizer
      68^<th> Annual Meeting of the Japanese Cancer Assosiation
    • Place of Presentation
      Yokohama, Japan
    • Year and Date
      2009-10-02
    • Related Report
      2009 Annual Research Report
  • [Book] 専門医のための薬物療法 血液2011

    • Author(s)
      小野孝明
    • Total Pages
      12
    • Publisher
      中外医学社
    • Related Report
      2011 Final Research Report
  • [Book] 癌と化学療法 高齢者のがん薬物療法-血液-2011

    • Author(s)
      大西一功
    • Total Pages
      5
    • Publisher
      癌と化学療法社
    • Related Report
      2011 Final Research Report
  • [Book] 癌と化学療法 慢性骨髄性白血病に対するイマチニブ治療-10年を振り返り-2011

    • Author(s)
      大西一功
    • Total Pages
      3
    • Publisher
      癌と化学療法社
    • Related Report
      2011 Final Research Report
  • [Book] 専門医のための薬物療法血液2011

    • Author(s)
      小野孝明
    • Total Pages
      12
    • Publisher
      中外医学社
    • Related Report
      2011 Annual Research Report
  • [Book] 癌と化学療法高齢者のがん薬物療法-血液-2011

    • Author(s)
      大西一功
    • Total Pages
      5
    • Publisher
      癌と化学療法社
    • Related Report
      2011 Annual Research Report
  • [Book] 癌と化学療法慢性骨髄性白血病に対するイマチニブ治療-10年を振り返り-2011

    • Author(s)
      大西一功
    • Total Pages
      3
    • Publisher
      癌と化学療法社
    • Related Report
      2011 Annual Research Report

URL: 

Published: 2009-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi